Abstract
Background The ability to non-invasively measure left atrial pressure would facilitate the identification of patients at risk of pulmonary congestion and guide proactive heart failure care. Wearable cardiac monitors, which record single-lead electrocardiogram data, provide information that can be leveraged to infer left atrial pressures.
Methods We developed a deep neural network using single-lead electrocardiogram data to determine when the left atrial pressure is elevated. The model was developed and internally evaluated using a cohort of 6739 samples from the Massachusetts General Hospital (MGH) and externally validated on a cohort of 4620 samples from a second institution. We then evaluated model on patch-monitor electrocardiographic data on a small prospective cohort.
Results The model achieves an area under the receiver operating characteristic curve of 0.80 for detecting elevated left atrial pressures on an internal holdout dataset from MGH and 0.76 on an external validation set from a second institution. A further prospective dataset was obtained using single-lead electrocardiogram data with a patch-monitor from patients who underwent right heart catheterization at MGH. Evaluation of the model on this dataset yielded an area under the receiver operating characteristic curve of 0.875 for identifying elevated left atrial pressures for electrocardiogram signals acquired close to the time of the right heart catheterization procedure.
Conclusions These results demonstrate the utility and the potential of ambulatory cardiac hemodynamic monitoring with electrocardiogram patch-monitors.
Plain Language Summary Heart failure is a prevalent disorder that is challenging to manage. Part of what makes heart failure management challenging is that the onset of symptoms can be insidious as there are few robust tools that a clinical can leverage to estimate when a patient is likely to experience an episode of acute heart failure. While elevated intracardiac pressures are a reliable harbinger of worsening heart failure, these pressures are typically measured using an invasive, gold-standard approach, which can only be performed in an inpatient setting. A non-invasive method for detecting higher pressures inside of heart would be especially helpful for identifying worsening heart failure in an expeditious manner in the home environment. For this reason, we developed an artificial intelligence model to detect elevated pressures inside the heart using a non-invasive signal, the electrocardiogram (ECG, or EKG), which can be acquired from a wearable patch monitor device. Our results demonstrate that the model provides a reliable platform for the non-invasive assessment of cardiac pressures using data that can be obtained in the outpatient setting.
Competing Interest Statement
D.S., R.A. and C.M.S. are named authors on a patent filed by MIT.
Funding Statement
This work is funded by Quanta Computer, who also provided the ECG patch monitors used in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All clinical studies in this manuscript were approved by the Institutional Review Board at the Massachusetts General Hospital. (Protocol #2020P000132 #2016P001855)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Access to de-identified clinical data is only available pending IRB approval.
